ACM
CTNM

Altium Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Altium Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-303,857
Closed -$2.12M – 21
2025
Q1 		$2.12M Sell
303,857
-30,143
-9% -$274K 5.11% 6
2024
Q4 		$4.89M Sell
334,000
-35,126
-10% -$556K 1.39% 27
2024
Q3 		$7.07M Sell
369,126
-60,214
-14% -$1.15M 2.08% 17
2024
Q2 		$7.56M Buy
+429,340
New +$6.91M 3.08% 13

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Altium Capital Management's CTNM Position: Q2 2025 in Review

Altium Capital Management sold out of Contineum Therapeutics (CTNM) in Q2 2025, closing a stake of 303,857 shares — an estimated $2.12M sold.

Altium Capital Management first reported a position in CTNM in Q2 2024 and held it in 4 quarters. The position peaked at $7.56M in Q2 2024. 70 funds tracked by Wall St. Rank hold CTNM as of Q2 2025.

  • Altium Capital Management reported no remaining Contineum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Altium Capital Management sold 303,857 Contineum Therapeutics shares in Q2 2025, an estimated $2.12M.
  • Altium Capital Management first reported a position in Contineum Therapeutics in Q2 2024 and held it in 4 quarters.
  • Altium Capital Management's Contineum Therapeutics position peaked at $7.56M in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2025.

Based on Altium Capital Management's 13F filing for Q2 2025.